Point72 Asset Management L.P. bought a new position in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 590,946 shares of the company's stock, valued at approximately $3,008,000. Point72 Asset Management L.P. owned 1.99% of Eliem Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new stake in shares of Eliem Therapeutics in the second quarter valued at about $59,000. SG Americas Securities LLC acquired a new position in shares of Eliem Therapeutics during the third quarter worth $60,000. Valence8 US LP purchased a new position in shares of Eliem Therapeutics in the third quarter valued at $61,000. Dimensional Fund Advisors LP acquired a new stake in Eliem Therapeutics during the 2nd quarter valued at $89,000. Finally, Chicago Partners Investment Group LLC acquired a new position in Eliem Therapeutics in the 3rd quarter worth $81,000. Institutional investors and hedge funds own 69.76% of the company's stock.
Eliem Therapeutics Trading Up 5.3 %
NASDAQ:ELYM traded up $0.16 on Tuesday, reaching $3.18. The stock had a trading volume of 194,332 shares, compared to its average volume of 486,688. Eliem Therapeutics, Inc. has a 12-month low of $2.35 and a 12-month high of $11.55. The stock has a market cap of $94.61 million, a P/E ratio of -6.00 and a beta of -0.39. The company has a 50-day moving average of $4.07 and a 200 day moving average of $6.17.
About Eliem Therapeutics
(
Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Read More
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
